From article:
Implications: Tanespimycin is a new class of
antineoplastic drugs Tanespimycin has demonstrated additive if not
synergistic interaction with Velcade based MM txs Tanespimycin has a
desirable iv infusion route of administration ( ROA)
Analysis: Tanespimycin
is a new class of drugs known as heat shock protein inhibitors (HSP).
The popularity of Velcade in the treratment of MM as emphasized in
recent ASH meeting will only encourage use of this drug. Whats even
more importnt is that the 80% cancer treatemnt facitities would like to
see an infusional agent availble to treat MM as they are not very happy
with the work of getting the oral drugs for patients without any
revenue for their effort. I think this drug has muach going for it.
Regards,
Craig Persel